Avadel Financial Statements From 2010 to 2026

Stocks USA . 
Stock . Avadel Pharmaceuticals PLC
AVDL Stock  USD 21.60  0.03  0.14%   
Avadel Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Avadel Pharmaceuticals' valuation are provided below:
Gross Profit
235.9 M
Profit Margin
(0)
Market Capitalization
2.1 B
Enterprise Value Revenue
8.1727
Revenue
248.5 M
There are over one hundred nineteen available fundamental signals for Avadel Pharmaceuticals PLC, which can be analyzed over time and compared to other ratios. We recommend to validate Avadel Pharmaceuticals' prevailing fundamental drivers against the all of the trends between 2010 and 2026. Market Cap is expected to rise to about 468.2 M this year, although Enterprise Value will most likely fall to about 201.8 M.

Avadel Pharmaceuticals Total Revenue

204.21 Million

Check Avadel Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Avadel Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.6 M, Interest Expense of 13.1 M or Selling General Administrative of 218.6 M, as well as many indicators such as Price To Sales Ratio of 7.91, Dividend Yield of 0.0 or PTB Ratio of 12.8. Avadel financial statements analysis is a perfect complement when working with Avadel Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Avadel Stock
Check out the analysis of Avadel Pharmaceuticals Correlation against competitors.

Avadel Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets135.8 M188.9 M171 M
Slightly volatile
Short and Long Term Debt Total1.9 M2 M53.2 M
Very volatile
Other Current Liabilities49.4 M47.1 M27 M
Slightly volatile
Total Current Liabilities30.5 M56.2 M40.3 M
Pretty Stable
Property Plant And Equipment Net12.7 M14.8 M9.4 M
Pretty Stable
Accounts Payable6.1 M8.4 M6.2 M
Slightly volatile
Cash62 M59.1 M35.8 M
Slightly volatile
Non Current Assets Total42.8 M34.5 M54.7 M
Pretty Stable
Non Currrent Assets Other368.2 K387.6 K5.8 M
Slightly volatile
Cash And Short Term Investments72.9 M84.8 M89.3 M
Slightly volatile
Net Receivables41.2 M39.2 M18.8 M
Slightly volatile
Common Stock Shares Outstanding114.9 M109.4 M52.6 M
Slightly volatile
Liabilities And Stockholders Equity135.8 M188.9 M171 M
Slightly volatile
Non Current Liabilities Total57 M47.8 M84.7 M
Pretty Stable
Other Current Assets3.7 M6.9 M4.4 M
Slightly volatile
Other Stockholder Equity1.1 B1 B498.3 M
Slightly volatile
Total Liabilities87.5 M103.9 M125 M
Pretty Stable
Property Plant And Equipment Gross12.5 M15.9 M9.2 M
Very volatile
Total Current Assets93 M154.3 M116.3 M
Slightly volatile
Short Term Debt635.8 K669.3 K7 M
Pretty Stable
Intangible Assets888.2 K935 K17.1 M
Slightly volatile
Common Stock Total Equity501 K527.4 K1.8 M
Slightly volatile
Common Stock825.1 K868.5 K1.9 M
Slightly volatile
Other Liabilities6.3 M6.6 M28.5 M
Pretty Stable
Other Assets10.2 M14.4 M15.3 M
Slightly volatile
Long Term Debt110.6 M105.4 M70.5 M
Slightly volatile
Property Plant Equipment2.2 M2.3 M4.9 M
Slightly volatile
Short Term Investments24.5 M25.8 M60.7 M
Very volatile
Good Will14.3 M15.2 M17.6 M
Slightly volatile
Short and Long Term Debt35.6 M33.9 M41.1 M
Slightly volatile
Long Term Debt Total171.9 M163.8 M75 M
Slightly volatile
Capital Surpluse491.4 M631.8 M454 M
Slightly volatile
Non Current Liabilities Other31.8 M31.8 M72.5 M
Slightly volatile
Deferred Long Term Asset Charges8.3 M9.3 M10.2 M
Slightly volatile
Net Invested Capital107.8 M66.5 M109 M
Pretty Stable
Net Working Capital112.5 M98.2 M75.9 M
Slightly volatile
Capital Stock720.2 K1.1 M578.2 K
Slightly volatile
Capital Lease Obligations1.9 M1.5 M2.6 M
Slightly volatile

Avadel Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization4.6 M3.1 M4.9 M
Pretty Stable
Interest Expense13.1 M12.5 M7.5 M
Slightly volatile
Selling General Administrative218.6 M208.2 M73.9 M
Slightly volatile
Other Operating Expenses255.4 M243.2 M106.4 M
Slightly volatile
Cost Of Revenue18.4 M17.6 M8.9 M
Slightly volatile
Total Operating Expenses237 M225.7 M97.6 M
Slightly volatile
Research Development27.2 M17.5 M23.7 M
Pretty Stable
Discontinued Operations4.2 M4.6 M4 M
Slightly volatile
Selling And Marketing Expenses1.6 K2.3 K1.8 K
Slightly volatile
Interest Income7.8 M14.4 M10.2 M
Pretty Stable
Reconciled Depreciation2.3 M2.4 M3.7 M
Slightly volatile
Extraordinary Items234.3 K246.6 K1.8 M
Slightly volatile

Avadel Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow23.2 M35.8 M28.7 M
Slightly volatile
Depreciation4.6 M3.1 M4.9 M
Pretty Stable
End Period Cash Flow62 M59.1 M35.8 M
Slightly volatile
Stock Based Compensation24.6 M23.4 M9 M
Slightly volatile
Issuance Of Capital Stock10.1 M10.6 M22.7 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio7.915.3214.172
Pretty Stable
Days Sales Outstanding10866.23147
Very volatile
Stock Based Compensation To Revenue0.0960.110.1709
Slightly volatile
Capex To Depreciation0.520.551.1506
Very volatile
EV To Sales7.945.0614.6862
Pretty Stable
Inventory Turnover0.820.871.9317
Slightly volatile
Days Of Inventory On Hand2534361.2 K
Slightly volatile
Payables Turnover1.171.881.4792
Very volatile
Sales General And Administrative To Revenue0.780.870.9545
Slightly volatile
Research And Ddevelopement To Revenue0.09820.10.5598
Slightly volatile
Capex To Revenue0.00480.0050.0661
Slightly volatile
Cash Per Share0.660.71.8786
Very volatile
Days Payables Outstanding1501581.2 K
Pretty Stable
Intangibles To Total Assets0.20.120.2105
Slightly volatile
Current Ratio2.882.473.7243
Pretty Stable
Receivables Turnover3.874.465.1964
Pretty Stable
Capex Per Share0.01020.01070.1399
Pretty Stable
Revenue Per Share1.211.61.5772
Pretty Stable
Interest Debt Per Share0.110.121.4446
Pretty Stable
Debt To Assets0.00890.00930.314
Very volatile
Graham Number4.512.724.6205
Slightly volatile
Operating Cycle3515031.1 K
Slightly volatile
Days Of Payables Outstanding1501581.2 K
Pretty Stable
Long Term Debt To Capitalization1.231.170.7217
Slightly volatile
Total Debt To Capitalization0.01930.02030.4354
Pretty Stable
Quick Ratio2.812.13.6068
Pretty Stable
Cash Ratio1.451.211.1793
Pretty Stable
Days Of Inventory Outstanding2534361.2 K
Slightly volatile
Days Of Sales Outstanding10866.23147
Very volatile
Fixed Asset Turnover8.0611.8415.2418
Very volatile
Debt Ratio0.00890.00930.314
Very volatile
Price Sales Ratio7.915.3214.172
Pretty Stable
Asset Turnover0.970.930.4518
Slightly volatile
Gross Profit Margin0.650.820.8524
Very volatile

Avadel Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap468.2 M445.9 M396.4 M
Slightly volatile
Enterprise Value201.8 M388.4 M344.6 M
Slightly volatile

Avadel Fundamental Market Drivers

Forward Price Earnings16.835
Cash And Short Term Investments73.8 M

Avadel Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Avadel Pharmaceuticals Financial Statements

Avadel Pharmaceuticals investors utilize fundamental indicators, such as revenue or net income, to predict how Avadel Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-5.1 M-4.9 M
Total Revenue194.5 M204.2 M
Cost Of Revenue17.6 M18.4 M
Stock Based Compensation To Revenue 0.11  0.10 
Sales General And Administrative To Revenue 0.87  0.78 
Research And Ddevelopement To Revenue 0.10  0.10 
Revenue Per Share 1.60  1.21 
Ebit Per Revenue(0.29)(0.30)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Avadel Pharmaceuticals is a strong investment it is important to analyze Avadel Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Avadel Pharmaceuticals' future performance. For an informed investment choice regarding Avadel Stock, refer to the following important reports:
How To Invest In Avadel
Details
Is Avadel Stock a good investment?
Details
What is Avadel Pharmaceuticals' Net Worth?
Details
Largest Pharmaceuticals Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Avadel Pharmaceuticals Correlation against competitors.
You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avadel Pharmaceuticals. If investors know Avadel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Avadel Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Revenue Per Share
2.57
Quarterly Revenue Growth
0.549
Return On Assets
(0)
Return On Equity
(0)
Understanding Avadel Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Avadel's accounting equity. The concept of intrinsic value - what Avadel Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Avadel Pharmaceuticals' price substantially above or below its fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Understanding that Avadel Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Avadel Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Avadel Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY